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Medical Cannabis Use Among Adults With Chronic Pain

Abstract
The purpose of this integrative literature review was to understand the effects of medical
cannabis for chronic pain management in adults. Anecdotal reports suggest use of medical
marijuana as a pain management could be an alternative to opioids and other medications which
have long term consequences. Potential uses span the health care continuum, from prescribed
outpatient symptom management, to acute care, extended care, home care and hospice treatment
settings. The methodology included a review and synthesis of relevant research articles from 2012
to 2018, written in the English language. The findings suggest medical cannabis has the potential
of effectively managing chronic pain in older adults. Adverse effects, if present, are mild and
resolve without intervention. Lower doses of medical cannabis were reported to be more effective
in treating chronic pain compared to higher doses. Inconsistencies in the efficacy of THC were
noted compared to CBD for managing neuropathic pain. Implication for nursing practice, policy,
education, and recommendation for future research were discussed along with study limitations.
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Introduction
With an ever-increasing cost of the current three trillion-dollar health care industry in the
United States (US) challenges in the management of chronic pain is of utmost concern. America is
experiencing a significant growth in the older adult population, and this trend is projected to
continue for at least the next decade. Accompanying the aging process, there is a corresponding
rate of chronic diseases, which goes hand in hand with chronic disease. However, the most recent
approach to managing chronic pain by health care providers has increasingly use of opioids.
Depending on their overall health status, the biological age of an older adult can range in age from
50 years and older. For instance, a growing number of 50-year-old individuals are diagnosed with
multiple chronic medical conditions, while some 80-year-old persons continues to be highly active
and in over all good health.
According to the National Institute of Health (NIH) there is an opioid misuse crisis. For
instance, of those who were prescribed opiates to manage their pain, at least thirty percent did not
adhere to the recommended dosage. (2018). Opioid over dosage is a public health crisis in our
country. The Centers for Disease Control (CDC) reports that on a daily bases, there are at least 200
deaths from drug overdose; of these, about 100 deaths are reported each day from opioid overdose.
(Sessions, 2018)
Considering this major public health concern, one option for a safer, less addictive, and
holistic alternative could be use of medical cannabis for pain management (Borreli, 2018).
However, there is on ongoing debate at a national level on weather cannabis should be legalized
for medicinal purposes. A growing number of states have voted to approve cannabis for medicinal
purposes. However, there continues to be resistance in its use by some providers as well as certain
segments of the population. Likewise, supporting evidence for use of cannabis is inconclusive and
sometimes contraindicated.
The usage of marijuana became stigmatized after the U.S. government launched a
campaign to tie the illicit substance known as “marihuana” to the influx of Mexican immigrants.
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At the time Americans didn’t know cannabis and “marihuana” were the same plant and after the
implementation of the Marijuana Tax Act in 1937 the usage of cannabis ultimately became illegal.
(Burnett and Reiman, 2014)
Additionally, pharmaceutical companies developed synthetic opioids. Consequently, health
care providers turned to opioids, which are highly addictive, for management of chronic pain. The
current national challenge is educating the public and modifying the public’s perception of
cannabis as ‘gateway drug’ to a ‘healthier’ alternative - use of opioids.
The population that struggles the most to accept and incorporate medical cannabis into their
treatment regime are older adults. (Satterlund et. al., 2015). Older individuals chose not to disclose
their usage of medical marijuana to anyone besides their spouse, according to the same study.
While both older and younger individuals were discrete about disclosing their status. In particular,
the elderly population showed significantly less disclosure to their closer social circle. Despite
being the most susceptible to experience chronic illnesses and pain, some older adults adhere to the
stigma that surrounds cannabis usage. Their reluctance is associated with in not being legalized, or
only very recently been legalized in the state in which they reside. This stigma involves an
individual’s fear of how they are perceived by their peers.
Medical practitioners disregard the current medical guidelines when treating chronic pain in
the older adult. Opioid prescriptions are discouraged for those experiencing chronic pain not
related to cancer, as a palliative intervention, or end-of-life hospice care (Le Roux, 2016). As of
2016, chronic pain is most commonly treated with opioids. Medical marijuana has been proven to
reduce the side effects of other medications and improved quality of life in its users by 45%.
(Boehnke, 2016). Considering cannabis is increasingly being accepted as an alternative pain
management modality, there is a need to evaluate the evidence on its treatment effect in the older
adult.
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Purpose
The purpose of this integrative review of the research literature is to examine the effects of
medical cannabis use among adults with chronic pain. The information could inform nurses of
alternatives to opioid use for pain management.

Problem statement
What are the effects of medical cannabis use among adults with chronic pain?
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Literature Review
To understand the effectiveness of medical marijuana a review of the literature is needed.
Adults of all ages may be prescribed medical marijuana the purpose for usage, however, varies.
Analyzing this is a key component towards assessing the effectiveness of medical marijuana for
pain management in the older adult population. Haug et al., compared cannabis use patterns and
motives among younger, middle-aged, and older adults. They found that younger adults reported
the highest in usage of cannabis to relieve boredom, or recreationally. Conversely, the older adult
population primarily use is for management of chronic health conditions or insomnia. (Haug et. al.,
2017). These findings indicated that while the perception among older adults of medical marijuana
was negative, the majority may have legitimate medical conditions that could possible benefit from
this treatment approach.
The article also stresses the use of medical marijuana by younger individuals may not apply
to the older adult population. In other words, while use of marijuana recreationally in one’s youth
has negative implications, this view may not be appropriate for the older adult population. In fact,
when appropriate prescribing of medical marijuana to the older adult could help to minimize the
aforementioned negative stigma. (Haug et. al., 2017).
The evidence suggests cannabis has no long-term side effects from usage. In addition,
medical marijuana can be administered in a various ways including smoking, vaporization, orally,
and transdermal. These administration options increase the likelihood of tolerance by an elderly
individual. In the elderly, opioid analgesic overdose poses more of a mortality risk than the usage
of medical marijuana. (Bachhuber et al., 2014)
Briscoe and Casarett discuss the challenges that accompany medicating older adults with
opioids. Side effects of opioids include, constipation, confusion, falls, fractures, metabolic
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disturbances, soft tissue injury, and even death in older adults with dementia. (2018)
Comparatively, the primary adverse effects of cannabis when used by older adults are dizziness
and dry mouth. In this study, medical marijuana was not reported to have the severe detrimental
adverse effects as opioids when used for pain management.
With the increasing age of the general population, substance use disorders are occurring
more frequently in older adults. Likewise, substance use disorders such as opioid addictions are
‘under-reported, under-detected, and under-treated’ (Le Roux et. al., 2016). Older adults tend to be
over looked when it comes to determining the extent of the opioid misuse coupled with their
growing problem of polypharmacy. This oversight impedes appropriately addressing current pain
management protocols with older adults. There also are physiological changes associated with
aging that impact the metabolism and excretion of medications, specifically opioids. Consequently,
older adults are highly vulnerable to serious medication side effects, and accidental overdoses or
with chronic pain management.
Eliminating opioids and providing alternative forms of pain medications such as medical
marijuana could be an approach to deal with the over use of opioids in older adults. In fact,
Boehnke found that cannabis use was associated with 64% lower opioid use to treat chronic pain
(2016). Medical cannabis has been shown to reduce pain and decrease polypharmacy with fewer
adverse side effects. Multiple routes of administration provide alternative options for older adults
who cannot tolerate oral medication. Medical marijuana in small doses could address the
emotional component of pain that often accompanies chronic illnesses. (Ware et al. 2002)
Preliminary findings in this limited literature review indicated there was a strong
correlation between chronic pain in the older adult and the opioid epidemic in that growing
segment of the population (Le Roux et al., 2016). Medical cannabis could also be an approach to
address polypharmacy which often accompanies opioid usage in this population (Briscoe &
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Casarett, 2018). Polypharmacy is defined as the treatment of one aliment with multiple drugs
simultaneously. Considering the increased use of this intervention, it is important that the research
evidence focusing on the effects of cannabis in the older adult be examined.
When examining the usage of medical marijuana for chronic pain management in the
elderly there is a need to address the safety and efficacy of the therapy. The current evidence is
based on surveys and self-reports rather than quantitative data. Abuhasira et. al. (2018)
implemented a prospective study to examine (N= 2,736) adults 60 years and older on their
experiences with medical cannabis delivered in capsule, cigarettes, oils, and inflorescence.
While Abuhasira et. al. (2018) analyses efficacy of medical cannabis in managing pain,
Ahmed et. al. (2014) used a randomized controlled trial to explore the safety and pharmacokinetics
of oral delta-9-tetrahydrocannabinol. Specifically, they focused on the older adults who were
healthy. This sample (N=11) had prior exposure to cannabis thus reducing the risk of user error.
While providing new insights to the pharmacokinetics of the drug through plasma concentration,
researchers were unable to examine the same effect on those currently experiencing pain.
Additional literature discusses specifically the effects of medical cannabis for neuropathic
pain. Mucke et. al. (2018) examines randomized, double-blind controlled trials on (N= 1,750)
adults experiencing neuropathic pain with a rating of 4 or more out of 10. Wilsey et. al. (2012)
undertook a double- blind, placebo controlled, crossover study focusing on the effects of vaporized
cannabis for neuropathic pain. In both studies the population studied is not directly focusing on
elderly adults.
Trends in the usage of marijuana be it medical or recreational provide insight to the most
significant application of the drug for the late middle-aged and older populations. Both Lloyd et.
al. (2018) and Salas-Wright (2016) address this aspect of marijuana usage prior to and through the
21st century. The discussion of what demographic is most likely to use marijuana and for what
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reason is discussed as well as health outcomes. These articles address comorbidities for use such as
chronic pain and possible risk for substance abuse.
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Methodology
This integrative literature review examined articles from peer reviewed professional
journals. Research articles were found through a search on relevant data bases including
Cumulative Index to Nursing and Allied Health Literature (CINAHL), Elton B. Stephens Co. Host
(Ebsco Host), Medical Literature On-line (Medline), and PubMed Central (PMC). The following
terms were used to acquire relevant research; medical marijuana, medical cannabis, pain
management, chronic pain, elderly, and older adults. Inclusion criteria included peer-reviewed
research articles published from 2012 to the present and written in the English language. Exclusion
criteria includes articles that were published in another language besides English, and articles
outside the specified publication date.
Initially when searching the databases, 194 articles were found. After application of
inclusion and exclusion criteria the number was reduced to 9 peer-reviewed articles. Two of the
studies were international publications and an additional two studies were acquired from
references. The total studies that are to be reviewed include 12 articles, of which, 6 pertain
specifically to the use of medical cannabis in the elderly population alone. (See Appendix: Figure
1: Consort Chart; Table 2: Table of Evidence.)
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Findings
There is a niche opening for medical marijuana in the elderly especially with the growing
number of older adults over 65 years of age (Turner, 2019). The evidence suggests increase in
usage of medical cannabis since 2000. From 2013 to 2016 marijuana use in late middle age and
older adults nearly double (7% to 13%) (Salas-Wright et. al., 2016). Their findings identified a
steady decline from 2005 where 55.07% of older adults were convinced that marijuana posed a
great risk to their health decreased. In 2014 this attitude decreased to 50.24%. (Salas-Wright et.
al., 2016) The findings linked accessibility with acceptability to the prevalence of increased
cannabis use from the year 2003 to 2014 (N= 723,283). This study excluded marijuana usage for
diagnosis of depression, anxiety, HIV/AIDS, and STD but included all other disease process that
may cause chronic pain.
The chronic pain that accompanies older adults with comorbid is a factor in self-medicating
with medical cannabis. From 2006 to 2013 the prevalence of marijuana use among older adults age
50 or higher increased by 71.4%. The majority reported for medicinal purposes rather than
nonmedicinal reasons. (Lloyd et. al., 2018) In this study, cannabis was universally beneficial as
treatment for chronic pain management. Cannabis can be a stand-alone therapy or an
accompaniment for individuals who treat pain with polypharmacy including opioids.
Salas-Wright et. al. (2016) examined the nationwide (N=723,283) usage of medical
cannabis in adults over the age of 65 years old. The researchers used a repeated, cross-sectional
data collection method obtained from self-reports. The subjects were required to have a history of
marijuana usage within the past 12 months. Any subject with a medical diagnosis of depression,
anxiety, HIV/AIDS or STDs were excluded from the study. The pharmacology and method of
consumption was not specified within the parameters. The results found that usage of medical
cannabis increased exponentially with the increased accessibility and legalization of the drug
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within the older adult population. Subsequently, negative risk perceptions and disapproval rates
decreased. No link was found between usage of marijuana and increased risk for substance abuse.
However, subjects were more likely to use other substances if a history of marijuana use was
present.
Lloyd and Striley (2018) analyzed the usage of marijuana in the older adult population over
the 21st century. The researchers conducted a literature review to examine the indications for selftreatment with marijuana in adults 65 years and older. They included research of medical
conditions where conventional treatment did not provide symptom improvement. There was no
specific pharmacological or route of administration noted. The findings included the majority of
older adults reporting usage of marijuana solely for medicinal purpose. When using marijuana
adverse effects were reduced but present ranging from respiratory issues, metabolic syndrome, and
mental health problems.
Abuhasira et. al. (2018) develop as prospective study that used self-report with 6 and 12month follow-up questionnaires to investigate the safety and efficacy of medical cannabis among
the elderly 65 years or older (N=2,736). Participation required a licensed physician’s authorization
for initiation of treatment with medical marijuana. Cancer associate pain, Parkinson’s disease,
Crohn’s disease, ALS, Ulcerative colitis, and multiple sclerosis were all qualifications for pain.
The researchers compared the analgesic properties of opioids with medical marijuana as all
subjects had a history of opioid use. Subjects were administering marijuana in the form of oil,
inflorescence, flowers, capsules, and cigarettes. After 6 months a 50% reduction in pain was
reported and nearly 60% of subjects cited medical cannabis as a successful therapy. Prior to
initiation of the therapy over half the participants reported a fall within the past 6 months whereas
6 months into the therapy only 21% reported falling once or more. This finding reduces the
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concerns for fall risk as patients did not increase their incidents of falls overall. In addition, nearly
20% of subjects stopped or reduced their use of opioid analgesics after initiating medical cannabis.
Ahmed et. al. (2014) researched the pharmacokinetics and safety of oral THC in healthy
adults (N=11) over the age of 65 years. A randomized double blind, double-dummy, placebo
controlled, cross-over trial was used. Subjects had no prior history of cannabis use and only mild
hypertension and hypercholesterolemia was observed in 3 of the participants prior to initiation of
therapy. THC was administered using a low 1.5 mg and high 5mg dose of Namisol. Common
adverse effects included drowsiness, dry mouth, coordination disturbances, and headache but
globally THC was well tolerated in older adults. An unexpected result proved the older population
tolerated THC better than the younger population counterparts.
Wilsey et. al. (2012) examined the efficacy of low-dose vaporized cannabis for neuropathic
pain. A randomized, double-blind, placebo controlled, crossover design was used to examine
adults (N=39) experiencing pain related to neuropathic conditions. Low-does THC (1.29%),
medium-dose THC (3.53%), and placebo cannabis were administered via “Foltin Puff Procedure”.
The researchers found that, compared to the placebo doses, THC yielded a significantly higher
equianalgesic effect. Cannabis was confirmed unsuitable in acute pain management in individuals
with neuropathic disorders.
Mucke et. al. (2018) created a randomized, double-blind controlled trial to examine
cannabis use for chronic neuropathic pain in adults (N=1,750). Subjects required a neuropathic
pain reported as 4 or above on the numeric pain intensity rating scale unsuccessfully reduced with
analgesic therapy in order to qualify. The primary method for administration of cannabis consisted
of herbal, plant-derived, and synthetic components. All forms of cannabis medications proved
better outcomes in general pain relief and global improvement compared to the placebo. A lack of
“high quality” evidence, which the researchers define as very confident the result acquired
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correlates to the estimated effect, was reported in the treatment of chronic neuropathic pain, an
unexpected result.
Bigand et. al. (2018) studied adults over the age of 18 years old (N=150) using a qualitative
self-report method to obtain the perceived benefits and adverse effects of cannabis use. All
participants took prescription opioid medication prior to the initiation of the study. Numerous
adverse effects were reported including fuzzy thinking, sleepiness, poor memory, overeating,
coughing, weight gain, burning red eyes, dry mouth, nausea, and increased heart rate. Subjects
reported the social and financial burden of medical cannabis usage deterred them from
continuation of cannabis therapy despite 67% endorsement from participants regarding the
alleviation of pain.
Reiman et. al. (2017) researched the efficacy of cannabis as an opioid substitution for
adults (N=2,987). A cross-sectional Qualtrics survey was used to gather data on the “HelloMD”
patient database. Chronic pain related conditions ranging from back pain, migraines, PMS,
Fibromyalgia, inflammation, and cancer were included. The subjects reported various methods of
administration including smoking (50%) followed by vaporizing (31%) and edibles (10%).
Cannabis users reported relief of their neuropathic symptoms without experiencing unwanted side
effects. In addition, 97% of respondents were able to decrease the intake of opioid medications
with concurrent use of cannabis. More participates reported stigma and obtainability as the primary
reason for decrease use of cannabis.
Nugent et. al. (2018) developed a multisite prospective cohort study to examine the patters
of medical cannabis and long-term opioid therapy. The researches examined adults (N=371)
experiencing musculoskeletal pain currently on long-term opioid therapy. Medical cannabis was
not associated with an increase in misuse of substances such as alcohol or nicotine. Additionally,
participants who endorsed medical cannabis reported decreased impairment due to medication
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related side effects compared to those denied medical cannabis use. Using medical cannabis also
lowered the experienced side effects from other opioid medications.
Boehnke et. al. (2016) examined the association between medical cannabis use and
decreased opioid medication using a cross-sectional retrospective study. Adults (N=374) with a
history of opioid usage for chronic pain management and registered medical cannabis licensure
were included. The researchers found that cannabis reduced the side effects experienced after the
administration of opioids and a 45% improvement in overall quality of life was reported.
Abuhasira et. al. (2018) and Ahmed et. al. (2014) examined the efficacy of medical
cannabis for chronic pain management demonstrated a strong case for the validity of the therapy.
In a prospective study of older adults above the age of 65, Abuhasira et. al. (2018) determined
cannabis a safe and efficacious form of therapy when analyzing quality of life, pain intensity, and
perception of general effectiveness. After six months of treatment, 60% of participants seeking to
gain moderate improvement in their condition view the cannabis therapy as successful in achieving
that goal. (Abuhasira et. al., 2018)
Ahmed et. al., (2014) analyzed the efficacy and safety of medical cannabis for (N=11)
older adults using delta-9-tetrahydrocannabinol (THC) in varying doses with 3 mg, 5 mg, and 6.5
mg doses including a placebo. (Ahmed et. al., 2014) Using a Visual Analog Scale, Attentional
Performance, and SwayStar to record their “feeling high”, alertness/reaction time, and body sway
respectively, only 4% of participants experienced “feeling high”. An unexpected finding was that
the mean age of older adults (72 years and older) demonstrated a superior tolerance to THC
compared to their younger counterparts. Participants attention performance and body sway was not
significantly disturbed during the course of their treatment using cannabis. (Ahmed et. al., 2014)
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Discussion
The next section highlights consistent and inconsistent findings from the reviewed articles
along with gaps in the literature.
Consistent Findings
When treating with a flexible dose design medical cannabis proved most effective at the
lower dosage end of the spectrum. Both Ahmed et. al. (2014) and Wilsey et. al. (2012) found this
phenomenon when treating participants with low, medium, high, and placebo doses (N=11) and
(N=39) respectively. The highest dosage given, 6.5 mg of THC, resulted in increased adverse
events while no significant instances were noted in the medium (5mg) and lower (3mg) doses.
(Ahmed et. al., 2014) Similarly, both the low (1.29% THC) and medium (3.53% THC) dose had
the same global effect on pain management which was significantly higher than the placebo.
(Wilsey et. al., 2012) In this study the lower dose was found to be superior when compared to the
medium dose in reducing aching pains.
No major side effects were found in clinical trials and client reports when using medical
cannabis. Side effects associated with respiratory issues (Salas- Wright et. al., 2016) related to
inhalation of toxins when smoking cannabis (Lloyd et. al., 2018) along with confusion and
psychosis (Mucke et. al., 2018). Dizziness, dry mouth, and drowsiness are the most common
adverse effects during the treatment. Only one study, Mucke et. al., 2018, had participants (N=
1,750) withdrawal due to adverse events. The adverse effects of medical cannabis treatment were
found to be less severe than opioids (Boehnke et.al., 2016). The findings also concluded medical
cannabis posed no significant limitation on activities of daily living due to adverse effects (Wilsey
et. al., 2012)
In comparison to opioid therapy for chronic pain management one fourth of the studies,
(Boehnke, et.al., 2016, Nugent, et.al., 2018, Reiman, et.al., 2017, and Vyas, et.al., 2017), found a
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reduction in opioid usage after initial treatment. Opioid overdose mortality rates have declined in
states with medical cannabis laws in place (Bachhuber et.al., 2014). Reiman et. al. (2017) used a
cross sectional survey to ask subjects (N=2,897) if treatment with cannabis as a stand-alone
therapy as opposed to a combination between cannabis and opioids was more effective, 81% of
participants “strongly agreed/ agreed with the statement. (Reiman et. al., 2017) Nugent et. al.
(2018) reaffirmed that medical cannabis was not only perceived as valuable for chronic pain
management in subjects (N=371), but also lowered opioid-related adverse effects. When
administer for chronic pain cannabis was associated with fewer side effects and a 64% decrease in
opioid use (Boehnke et. al., 2016). Cannabis in combination with opioid pain medications could
also reduce polypharmacy among older adults.
Inconsistent Findings
Mucke et. al. (2018) and Winlsey et. al. (2012) both used double blind placebo-controlled
studies to examine efficacy medical cannabis has on neuropathic pain in particular. The results
differ in that Mucke et.al. (2018) found no evidence to support the efficacy of cannabis for
neuropathic pain management in adults (N=1,750). Cannabis provided better outcomes in general
pain relief and global improvement compared to the placebo. However, the researchers determined
this was not a significant effect of medical cannabis. They determined cannabis adverse effects
included dizziness, sleep, and mental disturbances such as confusion, somnolence, and psychosis
were enough to denounce the clinical usefulness of the therapy. The researchers concluded that
only a minimal number of people could benefit from the long-term usage of cannabis-based
medicines. (This study used dronabinol, nabilone, and THC/CBD combination derived from the
plant.)
Winlsey et. al. (2012) investigated the efficacy of delta-9-tetrahydrocannabinol (THC) in a
low (2%), medium (3.53%), and high (8%) dosages in addition to the placebo. An interesting
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phenomenon occurred when subjects (N=39) took the high dosage who reported increased pain.
This level of pain was not experienced with the medium or low doses who reported a 30%
reduction in pain level compared to the placebo. Other side effects included a feeling of cognitive
impairment including slight memory loss. However, in spite of the adverse effects, no participants
withdrew from the study. This was significant, since 10.4% of participants withdrew from the
Mucke et.al. (2018) study, none of which were in the placebo group. Winlsey et. al. was able to
conclude the low dose THC is more effective in the treatment of neuropathic pain.
Inconsistencies within the literature could be partly explained by the various treatment
approach in each study. Mucke et. al. (2018) did not offer flexible dosages which could explain
high participant withdrawal and negative outcome. Winlsey et. al. experienced a negative outcome
with the highest dose of 8% THC. The flexible-dose design offered another approach to
therapeutic dosages. In particular lower doses being more effective for pain management.
Gaps in the Literature
The current research focused specifically on the older adult population. At this time the
elderly population is not specifically targeted for medical cannabis research associated with their
comorbidities. Most available research examines the effects of cannabis on adults over the age of
18 years. While older adults are incorporated into this broad age bracket, age is not the sole focus
of the research. The ability to narrow in on a specific age demographic provides an individualistic
look into the efficacy of marijuana for that population. Without multiple clinical studies to focus
on the older adult population specifically, a deficiency exists in the evidence.
The literature also fails to examine the biological differences in cannabis efficacy between
males and females as well as for racial variations. The literature covers medical cannabis in the
adult population without distinguishing between the two genders and by race. Genetic and
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metabolic variations could impact the dosage, tolerance and effectiveness in treating chronic pain
in these subpopulations
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Implications for Nursing
The next section highlights implications for nursing education, practice, policy and
research.
Education
Currently medical education does not include context on use of medical cannabis in the
hospital or long-term care setting. Implementing this information in the curriculum for medical
cannabis is not possible given the conflicting and incomplete evidence for clinical practice.
Researchers are still studying the pharmacokinetics of cannabis. As a result, pharmacology classes
do not teach the drug’s uses or efficacy as it is only viewed as an illicit substance. Nursing students
are not exposed to medical cannabis in any manner that advocates for the benefits it provides to
clients. In addition, there is a lack of continuing education in the nursing profession on medical
cannabis. As the drug continues to be legalized and adults are gaining access, educating nurses and
nursing students becomes a necessity. A collaborative effort needs to be made in the nursing
profession to increase the education on relevant drugs. As the patient advocate, it is the nurse’s
responsibility to be knowledgeable of the available alternative therapies for pain management,
including medical cannabis.
Practice
Implementing the use of medical cannabis in the nursing profession comes with its
challenges. Nurses must work with their client to educate on the interactions medical cannabis has
with their condition. The client needs to understand the benefits and risks the medical cannabis
poses. Health professionals in general, nurses in particular, must better understand palliative and
end of life care options especially for older adults. In addition to advocating medical cannabis for
chronic pain management nurses are able to confidently support the therapy as an opioid reducing
alternative. Medical cannabis is linked with a decrease in adverse effects and addiction caused by
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opioid therapy (Vyas et. al., 2017). Currently, dronabinol and nabilone are the only two oral
cannabis medications approved in the United States by the Food and Drug Administration.
(Ahmed et. al., 2014) Both medications are only prescribed for nausea and vomiting and there is
no oral cannabis-based medication for pain relief approved by the Food and Drug Administration.
For nurses to be capable of accurately educating and advocating for the patient, knowledge of what
is currently available to the client as an alternative for pain management is essential.
Policy
In the US, nurse practitioners are not able to prescribe medical marijuana, rather, they
evaluate an individual for appropriateness of this medication. Subsequentially, a referral is made to
a medical marijuana dispensary. In these cases a pharmacist works with the individual to achieve
the desired effects. This shift of responsibility from the nurse practitioner to the pharmacist is
associated with the deficit in cannabis prescription practices. The nurse practitioner often is wary
when evaluating clients for referral eligibility because the pharmacist is more educated on medical
cannabis. The disparity between the two providers ultimately affects the client who is unable to
find a nurse practitioner confident enough to complete the referral.
Another barrier in place for medical cannabis users is the cost. In the United States,
medical cannabis is not covered by insurance because it is classified as a Schedule I drug and
considered an illicit substance. When a state legalizes medical cannabis, it still remains under the
federal classification Schedule I drug, meaning “no medicinal value”. Third party payers are
subsequently allowed to deny coverage of medical cannabis. As a result, medical cannabis users
are forced to pay one-hundred percent of the costs out of pocket for the medication. Nurses must
keep this in mind when advocating use of medical cannabis for clients with chronic pain. A
discussion should be held between the nurse and the client to discuss financial stability.
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Research
As more research becomes available nurses will be able to educate themselves and future
clients on the efficacy of medical cannabis for chronic pain management. Future research should
examine the implications of medical cannabis at the bedside including what to monitor after
administration of the drug. Recommendation for further research using repeated quantitative,
clinical based trials of the same low dose cannabis on adults over the age of 65 may bridge the gap
in available literature. Examining flexible dose designs on male and female subjects individually
could also provide a varying prospective for cannabis administration. Additional studies are
needed to determine if there are genetic variations in the tolerance and effectiveness in racial
subgroups. Without a complete picture of what medical cannabis therapies offer a patient
experiencing chronic pain nurses are not able to advocate for the client.
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Summary
Strides are being made to understand the therapeutic indication of medical cannabis for
chronic pain management in the elderly. Cannabis use may be a safe and efficacious alternative
method of medication for chronic pain management in some adults. When used as an analgesic
that evidence supports there are minimum adverse events to accompany it. Ultimately some clients
are interested in using medical cannabis to reduce their polypharmacy and take control of their
quality of life. There is still a long way to go to break the legal and social barriers of medical
cannabis usage.
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APPENDIX A

FIGURE 1: CONSORT FLOW CHART
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Searched databases:
Cumulative Index to Nursing and Allied Health Literature
(CINAHL), Elton B. Stephens Co. Host (Ebsco Host),
Medical Literature On-line (Medline), and PubMed
Central (PMC)

Using Key terms:
Medical marijuana, medical cannabis, pain manageme nt,
chronic pain, elderly, and older adults n=194.

•
•

Exclusion:
Articles published in a language other
than English
Articles outside of the specified
publication date.

•

•
•
•
•

Inclusion criteria:
Peer reviewed research-based articles published in
professional journals
Articles written in the English language
Published from 2012 to 2018
International studies will be included in this review
process.

•
Studies that did not fit inclusion criteria or
were unattainable n=183.

After further review of studies n=9.

Additional studies acquired from references n=2.

Total studies to be reviewed n=11.

After further review, studies pertaining to only to the use
of medical cannabis in the elderly population alone n=6.
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APPENDIX B

TABLE I: TABLE OF EVIDENCE
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Last name of first
author/year

Study design
Dates

Sample size/data
collection
method

Categories/
Definitions of Pain

History of
Opioid use

Pharmacokineti Key Findings
cs/ Method of
consumption

Abuhasira/ Schleider/
Mechoulam/ Novack/
Israel/ 2018

Prospective study.
January 2015 –
October 2017

N= 2,736

Initiation of treatment with
medical marijuana under
authorization of a
physician.

Did not directly
address the usage
of opioids,
however, the
survey does
compare the
analgesic
qualities of
opioids with
medical
marijuana if
history of opioid
use is presented.

Medical
cannabis
administered in
the form of oil
and
inflorescence
distributed
through flowers,
capsules, and
cigarettes.

Did not address
the usage of
opioids.

A dosage of
1.5mg or 5 mg
Namisol tablets

Ahmed/ Elsen/ Colbers/
Marck/ Burger/ Feuth/
Rikkert/ Kramers/ 2014

Randomized, doubleblind, double-dummy,

Self-report
through initial, 6
months, and 12
months follow up
questionnaires.

N= 11

Qualifications for pain
include cancer associated
pain, nonspecific pain,
cancer, Parkinson’s
disease, Crohn’s disease,
Amyotrophic lateral
sclerosis, Ulcerative
colitis, multiple sclerosis.

No prior history of
cannabis usage.
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The usage of medical
cannabis resulted in a
50 percent reduction
of pain after 6 months
based on a pain rating
scale of 0 to 10.
Almost 60 percent of
participants reported a
successful outcome
after using medical
cannabis.
Over half of the
participants reported a
fall prior to the usage
of medical marijuana.
Within 6 months after
using medical
marijuana only 21%
of participants
reported falling once
or more.
A significant 18
percent of participants
reduced or stopped
using opioid
analgesics after
initiating cannabis for
pain management.
Common adverse
effects included
drowsiness, dry

Last name of first
author/year

Study design
Dates

Sample size/data
collection
method

Categories/
Definitions of Pain

History of
Opioid use

Pharmacokineti Key Findings
cs/ Method of
consumption

placebo controlled,
cross-over trial.

Blood sampling to
measure the
plasma
contractions of
THC, body sway,
TAP- alertness,
VAS- feeling
high.

In order to test the safety
and efficacy of medical
cannabis all participants
were in relatively healthy
shape. Hypertension and
hypercholesterolemia were
noted in 3 participants
respectively.

Participants were
excluded if a
history of drug or
alcohol abuse
was present.

were
administered.
Ingested orally.

mouth, coordination
disturbances, and
headache.
Cannabis was well
tolerated by older
individuals ages 65
and older.
The study proves
THC to be better
tolerated in the older
population compared
to the younger
population.

N= 150

Adults over the age of 18
currently prescribed
opioid medication for
pain, including cancer
pain.

Participants must
currently be
taking
prescription
opioid
medication.

Variation in
administration of
strength, dose,
and vessel.

Commonly reported
adverse effects of
medical cannabis
include fuzzy
thinking, sleepiness,
poor memory,
overeating, coughing,
weight gain, burning
red eyes, dry mouth,
nausea, and increased
heart rate.
Participants reported
judgement from others
as a negative social
consequence when
using cannabis.
Only 10.7% (N=16) of
the participants
reported current

August – November
2012

Bigand/ Anderson/
Roberts/ Shaw/ Wilson/
2018

Qualitative descriptive
content analysis
method, self-report.
No date available

Recruitment from
clinic waiting
rooms with
qualitative selfreported health
outcomes

Issues of physical pain
including insomnia,
reduced appetite, nausea
or symptoms caused by
cancer, scleroderma,
headache, neuropathies,
muscle spasms, and
Crohn’s disease.
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Last name of first
author/year

Boehnke/Litinas/Clauw/
2016

Study design
Dates

Cross-sectional
retrospective survey
November 2013 –
February 2015

Sample size/data
collection
method

N= 374
Survey of
Qualtrics (Provo,
UT)

Categories/
Definitions of Pain

Registered medical
cannabis participants from
local medical cannabis
dispensary.
Fibromyalgia Survey
Criteria (FM score) from 0
to 31. The most intense
pain equivalent to 31.
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History of
Opioid use

All participants
were required to
have a history of
opioid usage for
chronic pain
management.

Pharmacokineti Key Findings
cs/ Method of
consumption

Variation in
administration of
strength, dose,
and vessel.

registration as a
medical marijuana
patient.
For the alleviation of
pain, 67% of
participants endorsed
the use of cannabis.
The cost of cannabis
was reported a
significant strain on
finances that 53% of
respondents could not
afford regularly.
Cannabis significantly
reduce the side effects
experienced after the
administration of
opioids.
Patients reported
improvement in
overall quality of life
by up to 45%.
When used in
partnership with the
minimum amount of
opioids for pain
management cannabis
showed up to 95%
reduction in
administration. These
trends decrease as the
prescription opioids
increase.

Last name of first
author/year

Study design
Dates

Sample size/data
collection
method

Categories/
Definitions of Pain

History of
Opioid use

Pharmacokineti Key Findings
cs/ Method of
consumption

Lloyd/ Striley/ 2018

Systematic review of
the literature

N= N/A

Self-treatment for
unrelieved symptoms of
pain and recreational
usage.
Medical conditions with
symptoms that show no
signs of improvement with
conventional treatment.

Did not address
the usage of
opioids.

Variation in
administration of
strength, dose,
and vessel.

January 2000December 2017

Database search of
epidemiological
studies, human
subjects, English
language, peer
review
publications, and
U.S. populations
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The vast majority of
aging older adults use
marijuana strictly for
medical purposes with
age.
It has been associated
with lower adverse
effects, less risk for
addiction, and
increase benefits for
usage in treating
medical conditions.
Subsequentially
negative effects of
marijuana include
mental health
problems, respirator
issues, metabolic
syndrome, and drugdrug interactions.

Last name of first
author/year

Study design
Dates

Sample size/data
collection
method

Categories/
Definitions of Pain

History of
Opioid use

Pharmacokineti Key Findings
cs/ Method of
consumption

Mucke/ Phillips/
Radbruch/ Petzke/
Hauser/ 2018

Randomized, doubleblind controlled trials

N= 1,750

Adults had to be at least
35 with a pain rating of
above 4 experiencing
neuropathic pain.

Did not directly
address the usage
of opioids.

Variation in
administration of
strength, dose,
and vessel.
Primary method
include herbal,
plant-derived,
and synthetic.

Patients must be
currently on
Long-term
Opioid Therapy
which indications
history of opioid
use.

Variation in
administration of
strength, dose,
and vessel.

2000-2010

Nugent/ Yarborough/
Smith/ Dobscha/ Deyo/
Green/ Morasco/ 2018

Multisite prospective
cohort study
October 2016 –
November 2017

Numerical rating
scale of 0 to 10 to
report pain
intensity.

N= 371
Self-report
measurement with
the Pain
Medication

Participants either had to
report a grade of 4 or
higher on the pain
intensity scale or
experience prior
unsuccessful analgesic
therapy.

Documented
musculoskeletal pain
diagnosis within their
medical records.
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In regard to treatment
of chronic neuropathic
pain cannabis showed
no high quality
evidence of its
efficacy.
All forms of cannabis
medications proved
better outcomes in
general pain relief and
global improvement
compared to the
placebo.
Primary adverse
effects include
sleepiness, dizziness,
and confusion.
When treating
neuropathic pain in
particular the study
sites cannabis as the
third-line therapy after
anticonvulsant and
antidepressant
medications prove
unsuccessful.
Side effects from
medications were
lowered with usage of
medical cannabis.
Medical cannabis was
not associated with an
increase in misuse of

Last name of first
author/year

Reiman/ Welty/
Silomon/2017

Study design
Dates

Sample size/data
collection
method

Categories/
Definitions of Pain

Questionnaire
(PMQ)

Conditions included but
not limited to arthritis,
back, and neck/joint pain.

Cross-Sectional Survey N=2,897
2016-2017

HelloMD patient
database,
Qualtrics survey
site

Affirmation of usage of
medical marijuana for
substitution of opioid/non
opioid pain medications
Pain-related conditions
including back pain,
migraines, PMS,
Fibromyalgia,
inflammation, cancer, etc.
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History of
Opioid use

Thirty percent of
the study
population
reported using
opioids for pain
management
currently or
within the past
six months.

Pharmacokineti Key Findings
cs/ Method of
consumption

Variation in
administration of
strength, dose,
and vessel.
Primarily
smoking (50%)
followed by
vaporizing
(31%) then
edibles (10%)

substances such as
alcohol or nicotine.
Participants who
endorsed medical
cannabis reported
decreased impairment
due to medication
related side effects
compared to those
denied medical
cannabis use.
More participates
would use cannabis
frequently if it was
less stigmatized and
more obtainable.
A significant decrease
in opioid related
mortalities was
observed in states
with legalized medical
marijuana.

Last name of first
author/year

Study design
Dates

Sample size/data
collection
method

Categories/
Definitions of Pain

History of
Opioid use

Pharmacokineti Key Findings
cs/ Method of
consumption

Salas-Wright/ Vaughn/
Cummings-Vaughn/
Holzer/ Nelson/
AbiNader/ Oh/ 2016

Repeated, crosssectional data
collection

N= 723,283

Addressed the overall
usage of the late middle
age population (age 65 or
older) rather than a
specific relation to pain.

Did not address
the usage of
opioids.

Variation in
administration of
strength, dose,
and vessel.

All participants
underwent a
urine toxicology
screening;
however, the
specific usage of
opioids is not
applicable to this
study.

Administer via
“Foltin Puff
Procedure” a
cued-puff
system.

Self-reports of
12month
marijuana usage

The exclusion of
depression, anxiety,
HIV/AIDS, and STD
diagnoses was due to the
unobtainable variables in
the population.

Wilsey/Marcotte/
Deutsch/Gouaux/
Sakai/2012

Randomized, doubleblind, placebo
controlled, crossover
design
December 2009 –
March 2011

N=39
100-mm visual
analog scale,
Patient Global
Impression of
Change (PGIC)

Prior exposure to cannabis
was a requirement for
participation.
Pain related specifically to
neuropathic conditions
including peripheral
neuropathic pain, diabetic
neuropathy, idiopathic
peripheral neuropathy,
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Placebo
cannabis
Low-does THC
(1.29%)

With the increasing
accessibility and
legalization of
marijuana usage
among older adults
has increased
exponentially.
There is a link
between marijuana
users and other
substance usage,
however, no real
evidence has shown
increase risk for
substance abuse.
Marijuana disapproval
and risk perception of
marijuana usage
decreased as
marijuana use became
more prevalent and
overall disapproval
decreased.
THC yielded
significantly higher
equianalgesic effects
compared to the
placebo doses. The
results analyzing
neuropathic effects
showed that the
medium dosage was
less effective on both

Last name of first
author/year

Study design
Dates

Sample size/data
collection
method

Categories/
Definitions of Pain

postherpetic neuralgia,
brachial plexopathy, and
lumbosacral
radiculopathy.
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History of
Opioid use

Pharmacokineti Key Findings
cs/ Method of
consumption
Medium-dose
THC (3.53%)

burning and aching
pains compared to the
low dose.
No tolerance issues
were encountered over
the course of the trial.
In an assessment of
acute pain cannabis
proved less effective
making it not suitable
for acute pain
management.
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TABLE II: TABLE OF EVIDENCE SUMMARY TABLE OF PEER REVIEWED NONRESEARCH AND EXCLUDED RESEARCH LITERATURE
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Last name of First
Author/year
Bachhuber/ Saloner/
Cunningham/ Barry/ 2014

Topic/Research/Summary
Medical Cannabis Laws and Opioid Analgesic Overdose
Mortality in the United States
Non research, data analysis
An analysis of trends from 1999 to 2010 comparting medical
cannabis laws and overdose mortalities related to opioid
analgesics. As new legislature was passing each state was
accounted for the following year. States that had medical
cannabis laws were compared to states that did not. Overall
opioid overdose mortalities were significantly lower in states
that had medical cannabis laws accounting for both prescription
and illicit opioid usage.

Kaskie/ Ayyagari/ Milavetz/
Shane/ Arora/ 2017

The increasing Use of Cannabis Among Older Americans: A
Public Health Crisis or Viable Policy Alternative
Non research, Policy Study
This article reaches to examine the population of older
Americans using the age-period-cohort paradigm to explain the
rise in cannabis usage. It examines the current policies in place
for the use of medical marijuana and the implications it may
have on opioid therapy and end of life care. It concludes with
an open call to examine federal policy, public opinion, and
biomedical efficacy of medical marijuana.
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Key Statements
1. There is a direct causal link between
reduced state-level opioid overdose
mortalities and medical cannabis
laws.
2. In the past decades, opioid
prescriptions for noncancer pain has
doubled, and with it overdose deaths
have skyrocketed.
3. The mean rate of opioid analgesic
overdose deaths was 24.8% lower in
states that implemented medical
cannabis laws.
4. Patients with legitimate prescriptions
for opioid analgesics from a single
provider make up the majority of
opioid analgesic overdoses at 60%.
1. The older adult population within the
United States is expected to double
over the next two decades.
2. The baby boomers as a generation are
notably more tolerant and like to use
cannabis both recreationally and for
symptom management.
3. The primary demographic for
cannabis usage includes unmarried,
white men with a history of cannabis
usage prior to the age of 30.
4. According to recorded antecedents of
cannabis users over the age of 50, the
benefits of cannabis are experienced
without any negative outcomes.
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